Glimerid

Glimerid is a prescription oral medication whose active ingredient is glimepiride, a sulfonylurea class antidiabetic agent. It is supplied as tablets in the standard strengths used for type 2 diabetes management and is marketed within the European Union. Glimepiride works by stimulating insulin release from pancreatic beta‑cells, helping to lower elevated blood glucose levels. The medication is taken by mouth, once daily with breakfast, and requires regular monitoring of blood glucose.

Glimerid (glimepiride) is indicated for the oral management of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient.

- Improves glycemic control as part of a comprehensive diabetes treatment plan. - Can be combined with metformin or other oral antidiabetic agents when monotherapy is inadequate. - May be used in patients with mild to moderate renal impairment, with dose adjustment as needed. - Helps reduce fasting and post‑prandial blood glucose levels. - Provides an option for patients who prefer a once‑daily oral regimen.

Like other sulfonylureas, glimepiride may cause a range of adverse effects that vary in frequency and severity.

Common: - Mild hypoglycemia, especially if meals are skipped or delayed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity. - Skin rash or mild itching.

Serious: - Severe hypoglycemia leading to confusion, loss of consciousness, or seizures. - Allergic reactions such as angioedema or Stevens‑Johnson syndrome. - Hepatic dysfunction presenting as jaundice or elevated liver enzymes. - Hematologic abnormalities like leukopenia or thrombocytopenia.

Healthcare providers should evaluate several factors before prescribing Glimerid to ensure safe and effective use.

- Assess renal and hepatic function; dose may need adjustment in impairment. - Review patient history for prior sulfonylurea hypersensitivity or severe hypoglycemia. - Caution in elderly patients due to increased risk of low blood sugar. - Advise patients to maintain consistent meal patterns to avoid hypoglycemia. - Monitor blood glucose regularly, especially during therapy initiation or dose changes. - Consider pregnancy and lactation status; safety data are limited. - Avoid use in patients with known sulfonylurea receptor mutations.

Glimepiride can interact with other medicines, affecting its glucose‑lowering action or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels. - MAO‑B inhibitors (e.g., selegiline) that may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, as they may impair glucose tolerance. - Corticosteroids, which can increase blood glucose and require dose adjustments. - Alcohol, which can enhance hypoglycemia risk, especially when consumed with meals.